<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783922</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-Approval- Submitted</org_study_id>
    <nct_id>NCT04783922</nct_id>
  </id_info>
  <brief_title>An Update on Intracerebral Hemorrhage</brief_title>
  <official_title>An Update on Intracerebral Hemorrhage - A Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shifa Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shifa International Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shifa Clinical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intracerebral hemorrhage study is a multicenter , combination of prospective and&#xD;
      retrospective observational cohort study led by Dr. Muhammad Junaid Akram, PhD scholar at&#xD;
      Chongqing Medical University. Prof Dr. Qi Li will be the senior consultant for the study. The&#xD;
      study will be focusing on natural history, epidemiological , radiological, rehabilitative and&#xD;
      clinical aspects as well as the effect of various treatments on the hemorrhagic patients.&#xD;
&#xD;
      The study related data of the patients diagnosed with intracerebral hemorrhage will be&#xD;
      collected in prospective and retrospective ways. The prognostic data for the patients will be&#xD;
      assembled and collected via using different outcome measures at different points of time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be used to address the several key issues related to intracerebral hemorrhage.&#xD;
      The demographics, scores based upon disease severity , mRS, GCS, NIHSS scores will be&#xD;
      recorded at baseline and in the prospective and retrospective ways. The data obtained from&#xD;
      the registered patients will be used for future use , critical review by expert neurologists,&#xD;
      neurorehabilitative experts for further use and review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hematoma volume growth at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>To assess early hematoma volume growth at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcome at 3 months assessed by modified Rankin Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Assess functional outcome at 3 months by using mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurological deterioration assessed by NIHSS score at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>To assess early neurological deterioration by using NIHSS score at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurological deterioration assessed by NIHSS score at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>To assess early neurological deterioration by using NIHSS score at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurological deterioration assessed by NIHSS score at 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>To assess early neurological deterioration by using NIHSS score at 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perihematomal edema volume measurement at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>To measure the perihematomal edema volume growth at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perihematomal edema volume measurement at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>To measure the perihematomal edema volume growth at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perihematomal edema volume measurement at 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>To measure the perihematomal edema volume growth at 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular hemorrhage growth</measure>
    <time_frame>24 hours</time_frame>
    <description>To assess the presence of IVH at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major thrombotic events</measure>
    <time_frame>2 weeks</time_frame>
    <description>To assess the thrombotic events 2 weeks after admission</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Stroke</condition>
  <condition>Hematoma</condition>
  <arm_group>
    <arm_group_label>Benign Hematoma</arm_group_label>
    <description>Patients (having novel image markers or clinical features) suggestive of a benign hematoma relatively , that is having relatively good prognostic outcome and less likely to expand.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant Hematoma</arm_group_label>
    <description>Patients (having novel image markers or clinical features) suggestive of a malignant hematoma relatively, that is more likely to expand and have poor prognostic outcome.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be comprising of the participants willing to participate in the&#xD;
        study with an age greater than 18 years from Pakistan.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years Patients willing to participate via signing a consent form' Patients&#xD;
             diagnosed with CT-Confirmed spontaneous intracerebral hemorrhage (ICH) Patients&#xD;
             willing to participate in the follow up assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing to participate Secondary ICH to hemorrhagic infarction or tumor bleeding&#xD;
             etc. Traumatic ICH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Junaid Akram, DPT, MS-NMPT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing Medical University, Chongqing / Shifa Tameer e Millat University, Islamabad</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Junaid Akram, DPT, MS-NMPT</last_name>
    <phone>0092-335-1402214</phone>
    <email>drjunaidmalik2@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muhammad Junaid Akram</last_name>
    <phone>0092-335-1402214</phone>
    <email>drjunaidmalik2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shifa Tameer e Millat University</name>
      <address>
        <city>Islamabad</city>
        <zip>46000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Junaid Akram, PhD*</last_name>
      <email>drjunaidmalik2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shifa Clinical Research Center</investigator_affiliation>
    <investigator_full_name>Dr. Muhammad Junaid Akram</investigator_full_name>
    <investigator_title>Dr. Muhammad Junaid Akram</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

